[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 90 of about 90
1. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol; 2006 Jul;1(6):591-601
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
  • BACKGROUND: This clinical practice guideline, based on a systematic review, was developed to determine which chemotherapeutic agents (or combinations of agents) show the highest response rates, improved survival, quality of life, or symptom control in patients with advanced malignant pleural mesothelioma.
  • CONCLUSIONS: There is good evidence to recommend chemotherapy with pemetrexed and cisplatin for adult patients with symptomatic advanced malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mesothelioma / drug therapy. Mesothelioma / mortality. Pleural Neoplasms / drug therapy. Pleural Neoplasms / mortality. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409924.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 0 / Quinazolines; 0 / Thiophenes; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 133
  •  go-up   go-down


2. Argote-Greene LM, Chang MY, Sugarbaker DJ: Extrapleural pneumonectomy for malignant pleural mesothelioma. Multimed Man Cardiothorac Surg; 2005 Jan 1;2005(628):mmcts.2004.000133
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapleural pneumonectomy for malignant pleural mesothelioma.
  • Extrapleural pneumonectomy was introduced in the 1940s for the treatment of extensive infections of the lung and pleural space.
  • Over the past 20 years, the extrapleural pneumonectomy technique has been modified and applied to the treatment of locally advanced malignant pleural mesothelioma, achieving substantial reductions in mortality.
  • The current mortality rate of 3.4% at the Brigham and Women's Hospital has permitted us to expand our use of this operation to treat locally advanced lung cancer and thymoma.
  • (1) Incision and exposure of the parietal pleura: (2) Dissection of the tumor and parietal pleura from the chest wall, diaphragm, and mediastinum: (3) Division and control of the pulmonary vessels and bronchus followed by lymph node dissection: (4) En bloc resection of the lung, pleura, pericardium, and diaphragm;.
  • The technique discussed below is the culmination of 20 years' experience with malignant pleural mesothelioma at the Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA USA.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24414726.001).
  • [Journal-full-title] Multimedia manual of cardiothoracic surgery : MMCTS
  • [ISO-abbreviation] Multimed Man Cardiothorac Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol; 2006 May;1(4):289-95
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
  • INTRODUCTION: Extrapleural pneumonectomy (EPP) and adjuvant high-dose radiation therapy (RT) are associated with a median survival of 3 years in early-stage malignant pleural mesothelioma (MPM) but of less than 1 year in locally advanced disease.
  • We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival.
  • CONCLUSION: Induction chemotherapy with gemcitabine and cisplatin followed by EPP and adjuvant RT for locally advanced MPM is feasible and leads to a better median overall survival than that previously reported with EPP and RT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409872.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol; 2009 Jan;4(1):97-101
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
  • This class of compounds has demonstrated anticancer activity in malignant mesothelioma.
  • We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma.
  • METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible.
  • CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma.
  • Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):804-10 [18245542.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):151-63 [12589032.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):721-8 [12939461.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1053-60 [3473246.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17174-9 [2211619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):2063-8 [9677468.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] J Transl Med. 2007;5:49 [17935615.001]
  • [Cites] Invest New Drugs. 2008 Feb;26(1):81-7 [17960324.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1400-10 [18027850.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):427-36 [11821955.001]
  • (PMID = 19096314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM062209; United States / NCI NIH HHS / CA / N01CM62209; United States / NCI NIH HHS / CM / N01 CM-62209
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Sulfonamides; F4H96P17NZ / belinostat
  • [Other-IDs] NLM/ NIHMS107784; NLM/ PMC3263397
  •  go-up   go-down


5. Roberts HC, Patsios DA, Paul NS, DePerrot M, Teel W, Bayanati H, Shepherd F, Johnston MR: Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol; 2009 May;4(5):620-8
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
  • Parenchymal nodules were followed according to lung cancer screening recommendations, morphology and location of pleural plaques was noted in detail.
  • We found plaques in 357 subjects (69.2%), commonly calcified (79.6%), flat (86.6%), and symmetric (86.8%), and mostly involving the costal (96.4%) and diaphragmatic (81.8%) pleura.
  • In 41 individuals, plaques were regarded as atypical; three had new pleural/peritoneal abnormalities on annual repeat LDCT.
  • An interim limited computed tomography of the observed abnormality prompted 10 diagnostic biopsies, resulting in a diagnosis of six lung cancers, two pleural mesothelioma and two peritoneal mesothelioma; overall rate of screen-detected malignancies is 2.1%.
  • There were four interval cancers, diagnosed after baseline (n = 1) or after the annual repeat (n = 3): two pleural and one peritoneal mesothelioma, and one mixed squamous/small cell carcinoma.
  • CONCLUSION: Screening prior asbestos workers detects advanced malignant pleural mesothelioma and early as well as late stage lung cancer.
  • We expect to learn more about the appearance of "early mesothelioma" with continued screening.
  • [MeSH-major] Asbestos / adverse effects. Carcinogens. Lung Neoplasms / radiography. Mesothelioma / radiography. Occupational Exposure / adverse effects. Pleural Neoplasms / radiography. Tomography, X-Ray Computed


6. Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T, Tsujimura T: Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol; 2010 Nov;23(11):1458-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
  • Malignant pleural mesothelioma is a refractory tumor with poor prognosis associated with asbestos exposure.
  • Pleural effusion is frequently observed in patients with malignant pleural mesothelioma, and cytological analysis is effective to detect malignant pleural mesothelioma.
  • However, cytological discrimination between malignant pleural mesothelioma and reactive mesothelium is often difficult.
  • Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.
  • In this study, to evaluate the diagnostic utility of CD146 for discrimination between malignant pleural mesothelioma and reactive mesothelium, we examined immunocytochemical expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody, OJ79 and EPR3208, on smear specimens of effusion fluids.
  • CD146 expression was detected in 15 of 16 malignant pleural mesothelioma with median immunostaining score of 3 by OJ79, and in 19 of 21 malignant pleural mesothelioma with median immunostaining score of 2 by EPR3208.
  • Strong immunoreactivity of CD146 was observed at the apposing surfaces of cell-cell interactions on the plasma membrane of mesothelioma cells.
  • In addition, one OJ79-negative case of malignant pleural mesothelioma was positive for CD146 by EPR3208 and two EPR3208-negative cases of malignant pleural mesothelioma were CD146 positive by OJ79, showing that all 23 malignant pleural mesothelioma cases were positive for CD146 by either OJ79 or EPR3208.
  • We propose that CD146 is a sensitive and specific immunocytochemical marker enabling differential diagnosis of malignant pleural mesothelioma from reactive mesothelium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelium / immunology. Immunohistochemistry. Mesothelioma / immunology. Pleural Effusion, Malignant / immunology. Pleural Neoplasms / immunology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657552.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD146; 0 / Biomarkers, Tumor; 0 / MCAM protein, human
  •  go-up   go-down


7. Ramalingam SS, Belani CP: Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol; 2008 Sep;3(9):1056-64
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma clinically manifests after decades of initial exposure to etiologic agents, such as asbestos, and presents with nonspecific symptoms such as dyspnea, pain, or weight loss.
  • The combination of cisplatin and pemetrexed, a novel multitargeted antifolate agent, is the approved "standard of care" for patients with unresectable malignant pleural mesothelioma.
  • A number of molecularly targeted agents are currently under evaluation for mesothelioma such as the Histone deacetylase (HDAC) inhibitors that have demonstrated promising anticancer activity.
  • Vorinostat, a small molecule inhibitor of HDAC, which targets select members of class I and II HDACs, has shown early evidence of activity and is currently being evaluated in a randomized study for patients who progress with standard therapy for advanced mesothelioma.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758312.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


8. Martin M: Clinical Experience With Pemetrexed in Breast Cancer. Semin Oncol; 2006 Feb;33 Suppl 2:15-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed possesses antitumor activity in several solid tumors, including non-small cell lung cancer, malignant pleural mesothelioma, pancreas, colorectal, gastric, bladder, breast, and head and neck cancers.
  • Pemetrexed has been tested in five phase II trials in locally advanced or metastatic breast cancer.
  • The drug has shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140044.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol; 2008 Apr 1;26(10):1698-704
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
  • PURPOSE: This multicenter, phase III study compared overall survival (OS) of second-line pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced malignant pleural mesothelioma (MPM).
  • CONCLUSION: Second-line pemetrexed elicited significant tumor response and delayed disease progression compared with BSC alone in patients with advanced MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Nov 1;26(31):5139-40 [18838696.001]
  • (PMID = 18375898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


10. Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg; 2008 Jun;14(3):161-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
  • PURPOSE: Despite extensive clinical research, no effective therapy for advanced malignant pleural mesothelioma has been established.
  • MATERIAL AND METHODS: Our study included 6 consecutive patients with malignant pleural mesothelioma (stage III: 5; stage IV: 1).
  • Because of the advanced stage of the disease, none of the patients underwent tumor resection or pleurectomy.
  • Tumor cells collected from pleural effusions pre-and at 0, 24, and 48 h postperfusion were examined using an immunocytochemical stain to determine apoptosis.
  • CONCLUSION: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cisplatin / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Perfusion. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577894.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Tanaka A, Takahashi T: [Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis]. Nihon Kokyuki Gakkai Zasshi; 2009 May;47(5):383-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
  • We report the case of a 68-year-old man with malignant pleural mesothelioma who was successfully treated with 4 lines of systemic chemotherapy and pleurodesis.
  • The diagnosis was made by cytological examination of pleural effusion, using the cell block method for immunochemical staining.
  • This first-line chemotherapy was repeated for 20 cycles, leading to maintained partial regression of the tumor and pleural effusion.
  • After 16 months, recurrence of the tumor with pleural effusion was observed, and single agent vinorelbine as second-line treatment (6 cycles) and single agent gemcitabine as third-line treatment (6 cycles) were administered sequentially.
  • It is suggested that combination of several systemic chemotherapy lines and regional disease control such as pleurodesis may be effective for disease control in patients with advanced malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514499.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


12. Vachani A, Moon E, Wakeam E, Albelda SM: Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol; 2010 Apr;42(4):385-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy for mesothelioma and lung cancer.
  • Both malignant pleural mesothelioma and advanced stage lung cancer are associated with a poor prognosis.
  • [MeSH-major] Genetic Therapy / methods. Lung Neoplasms / therapy. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Respir Cell Mol Biol. 2010 Apr;42(4):383-4 [20228386.001]
  • (PMID = 20160042.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / RNA, Antisense
  • [Number-of-references] 66
  •  go-up   go-down


13. Dowell J, Taub R, Lan C, Xie Y, Dunphy F, Blake V, Kindler H: A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM). J Clin Oncol; 2009 May 20;27(15_suppl):7578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).
  • Pt characteristics: male 88%; median age 66 (range 24-81); histology: epithelial 62%, sarcomatoid 15%, biphasic 20%, unknown 3%; site of origin: pleural 85%, peritoneal 12%, tunica vaginalis 3%; PS 0 32%, PS 1 68%; thrombocytosis (>400) 32%.
  • CONCLUSIONS: These data suggest that the addition of B to PC does not improve PFS when compared with historical controls of PC in advanced MM pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963386.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gregorc V, Ceresoli GL, Zucali PA, De Braud FG, Bajetta E, Santoro A, Viganò MG, Caligaris-Cappio F, Lambiase A, Bordignon C: Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM). J Clin Oncol; 2009 May 20;27(15_suppl):7582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM).
  • METHODS: Patients with advanced MPM were treated with a low-dose of NGR-hTNF given intravenously at 0.8 μg/m<sup>2</sup> as 1-hour infusion every 3 weeks (q3w).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hida T, Ogawa S, Park J, Park J, Shimizu J, Horio Y, Yoshida K, Sekido Y: Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):e19060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor.
  • : e19060 Background: Malignant pleural mesothelioma is asbestos-related malignancy that is highly resistant to current therapeutic modalities.
  • Survival of patients with malignant mesothelioma is very poor, especially in advanced stage, regardless of a recent advancement of chemotherapeutical modalities of combination with cisplatin and antifolate.
  • METHODS: Eleven cell lines derived from malignant mesothelioma were established in our laboratory.
  • RESULTS: Anti-cancer agents, cisplatin, vinorelbine, gemcitabine, gefitinib, or erlotinib, showed little growth inhibition, and pemetrexed and irinotecan showed modest growth inhibition in malignant mesothelioma cells, whereas amrubicin-13-OH showed strong growth inhibition.
  • Cyclooxygenase 2 inhibitors inhibit proliferation of malignant mesothelioma cells in a dose-dependent manner: modest growth inhibition at clinically achievable low concentrations and complete growth inhibition at clinically achievable high concentrations by intrapleural instillation.
  • CONCLUSIONS: Our study suggests that amrubicin can inhibit proliferation of malignant mesothelioma cells.
  • In addition, the use of a cyclooxygenase 2 inhibitor may be a promising therapeutic approach in the treatment of mesothelioma, because previous studies indicated the presence of increased cyclooxygenase 2 expression in malignant mesothelioma, which is notoriously resistant to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962139.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Srivastava V, Dunning J, Au J: Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis? Interact Cardiovasc Thorac Surg; 2009 Apr;8(4):454-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?
  • The question addressed was: Does video-assisted thoracoscopic (VATS) decortication in advanced malignant mesothelioma improve prognosis?
  • We conclude that VATS decortication is useful as a palliative measure in advanced malignant mesothelioma.
  • [MeSH-major] Drainage. Mesothelioma / surgery. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Benchmarking. Biopsy. Evidence-Based Medicine. Humans. Palliative Care. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / surgery. Predictive Value of Tests. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136533.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 6
  •  go-up   go-down


17. Reck M, Heigener DF, Gatzemeier U: [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]. Zentralbl Chir; 2008 Jun;133(3):238-42
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
  • Chemotherapy of malignant mesothelioma is of great importance because most patients with malignant pleural mesothelioma are diagnosed for the first time with widespread or advanced disease.
  • After the introduction of modern antifolates in the chemotherapy for malignant mesothelioma and after the establishment of standardised response criteria, a significant prolongation of survival time by combination chemotherapy was shown in two randomised phase III trials.
  • The combination of pemetrexed and cisplatin is the current standard of chemotherapy in malignant mesothelioma.
  • In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563688.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glutamates; 0 / Quinazolines; 0 / Thiophenes; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 29
  •  go-up   go-down


18. Ceresoli GL, Gridelli C, Santoro A: Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist; 2007 Jul;12(7):850-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of malignant pleural mesothelioma.
  • The incidence of malignant pleural mesothelioma (MPM) is increasing worldwide, and is predicted to peak in the next 10-20 years.
  • Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease.
  • [MeSH-major] Combined Modality Therapy / methods. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673616.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


19. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L: [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma]. G Ital Med Lav Ergon; 2007 Jul-Sep;29(3 Suppl):335-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
  • [Transliterated title] Utilizzo di biomarkers nella prevenzione e diagnosi precoce del Mesotelioma Maligno della pleura.
  • Improved detection methods for diagnosis of asymptomatic malignant pleural mesothelioma (MPM) are essential for an early and reliable detection and treatment of this disease.
  • The combination of 80HdG, VEGFbeta and SMRPs best distinguished the individual groups, suggesting a potential indicator of early and advanced MPM cancers.
  • The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
  • [MeSH-major] Biomarkers, Tumor / blood. Mesothelioma / diagnosis. Mesothelioma / prevention & control. Pleural Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409713.001).
  • [ISSN] 1592-7830
  • [Journal-full-title] Giornale italiano di medicina del lavoro ed ergonomia
  • [ISO-abbreviation] G Ital Med Lav Ergon
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Sugarbaker DJ, Wolf AS: Surgery for malignant pleural mesothelioma. Expert Rev Respir Med; 2010 Jun;4(3):363-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for malignant pleural mesothelioma.
  • The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy.
  • The former is indicated for patients with advanced locally invasive disease; the latter for patients with more superficial spread of tumor that spares the lung and fissures.
  • Despite having more advanced disease, a subset of patients with favorable prognostic factors can experience extended survival by undergoing trimodality therapy with extrapleural pneumonectomy, chemotherapy and/or radiation.
  • Much of what we know about the biology of mesothelioma has been gleaned from studying the surgical pathophysiology, including the delineation of histopathologic subtypes, disease stage stratification with survival, the propensity for local (in contrast to systemic) recurrence, as well as the prognostic effect of epithelial versus nonepithelial cell type, extrapleural nodal involvement, tumor bulk and surgical margins.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Thoracic Surgical Procedures

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524919.001).
  • [ISSN] 1747-6356
  • [Journal-full-title] Expert review of respiratory medicine
  • [ISO-abbreviation] Expert Rev Respir Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


21. Vural M, Abali H, Oksuzoglu B, Akbulut M: An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma. Cancer Invest; 2006 Oct;24(6):615-20
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma.
  • Additionally, the radiological diagnosis of thymoma can be differentiated easily from malignant pleural mesothelioma in most cases.
  • Here, we report a case of advanced thymoma mimicking malignant pleural mesothelioma, with circumferential encasement of the lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982467.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer; 2010 Oct;70(1):43-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related aggressive tumor.
  • Elevated serum and tissue EGFR is significantly associated with advanced disease stage.
  • High pre-treatment levels of serum EGFR are associated with advanced stage but not with reduced OS.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Mesothelioma / enzymology. Pleural Neoplasms / enzymology. Receptor, Epidermal Growth Factor / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20347505.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


23. Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, Walsh GL, Swisher SG, Hofstetter WL, Ordonez NG, Smythe WR: Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg; 2005 Dec;80(6):1988-92; discussion 1992-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended surgical staging for potentially resectable malignant pleural mesothelioma.
  • BACKGROUND: Extrapleural pneumonectomy for malignant pleural mesothelioma (MPM) is a high-risk procedure, and patients require careful preoperative staging to exclude advanced disease.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / surgery. Neoplasm Staging / methods. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Dec;82(6):2337; author reply 2337-8 [17126172.001]
  • (PMID = 16305830.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ: Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol; 2006 Jan;1(1):25-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
  • PURPOSE: To investigate the toxicity and effectiveness of pemetrexed maintenance therapy (PMT) in patients with malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Eligible were patients with histologically proven advanced MPM, WHO PS 0-2 and adequate hematological, renal and hepatic function in whom during 6 courses of pemetrexed containing induction therapy no disease progression was observed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409823.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


25. Patel SN, Kettner NW: Malignant pleural mesothelioma: a case report. J Manipulative Physiol Ther; 2005 Nov-Dec;28(9):724-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: a case report.
  • OBJECTIVE: The aim of this study was to discuss a case of malignant pleural mesothelioma (MPM) that presented to a chiropractic teaching clinic and review the pathophysiology of diseases associated with asbestos exposure.
  • A significant collection of pleural effusion was seen on the right side on plain film radiographs.
  • A chest computed tomography with contrast showed a large right-sided pleural effusion with small consolidation at the right lung base suggestive of pleural or pulmonary malignancy and highly suspicious for MPM.
  • An extrapleural pneumonectomy was performed, and specimens of parietal and visceral pleura were sent for pathological, which revealed a definitive diagnosis of spindle cell mesothelioma.
  • INTERVENTION AND OUTCOME: The patient was diagnosed with MPM, and a surgical therapy option was considered because of the aggressive nature of the lesion and her advanced age.
  • An extrapleural pneumonectomy was performed with removal of parietal and visceral pleura, right lower lobe, and right hemidiaphragm.
  • CONCLUSION: This is an unusual case of advanced MPM that is most likely from indirect asbestos exposure.
  • [MeSH-major] Mesothelioma / physiopathology. Pleural Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326244.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


26. Tamura E, Kozaki M, Kunimoto M, Tokuyama S, Kawanami Y, Watanabe H, Hamada T, Morooka M, Mukae H: [A case of localized malignant pleural mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jul;48(7):511-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of localized malignant pleural mesothelioma].
  • A chest computed tomography (CT) scan revealed a 5-cm mass attached to the pleura involving the right upper lobe, and a nodule in the right middle lobe.
  • Chemotherapy was initiated for advanced-stage lung cancer, but was not effective.
  • Histopathologic and immunohistochemical examinations after CT-guided needle biopsy revealed malignant mesothelioma.
  • There was local tumor invasion and metastasis in the lung and brain, without diffuse pleural spread.
  • This is a rare and important case of localized malignant mesothelioma pathologically confirmed by biopsy.
  • [MeSH-major] Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684215.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Azim HA Jr, Gaafar R, Abdel Salam I, El-Guindy S, Elattar I, Ashmawy A, Khorshid O: Soluble mesothelin-related protein in malignant pleural mesothelioma. J Egypt Natl Canc Inst; 2008 Sep;20(3):224-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related protein in malignant pleural mesothelioma.
  • BACKGROUND AND PURPOSE: Building-up evidence suggests that soluble mesothelinrelated protein (SMRP) carries a diagnostic and a prognostic value in malignant pleural mesothelioma (MPM).
  • The mean SMRP concentrations were significantly higher in patients with advanced disease (p = 0.038), poor performance status (p = 0.017) and high alkaline phosphatase (p = 0.015).
  • KEY WORDS: Malignant pleural mesothelioma (MPM) - Soluble mesothelin related protein (SMRP)- Sensitivity - Specificity - Asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424652.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


28. Halstead JC, Lim E, Venkateswaran RM, Charman SC, Goddard M, Ritchie AJ: Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol; 2005 Apr;31(3):314-20
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
  • AIMS: Malignant mesothelioma is increasing in incidence and no current therapy significantly prolongs survival.
  • We present the results of VATS debulking pleurectomy-decortication in advanced disease.
  • METHODS: A consecutive series of patients with suspected malignant mesothelioma underwent thoracoscopic assessment to determine the feasibility of decortication, where this was not possible a biopsy alone was taken.
  • The two groups (biopsy only and pleurectomy-decortication) were composed of patients with histologically confirmed mesothelioma [28 and 51 patients, respectively].
  • CONCLUSION: VATS pleurectomy-decortication is feasible in the majority of cases and independently improves survival for patients with advanced malignant mesothelioma.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780570.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Gupta V, Krug LM, Laser B, Hudka K, Flores R, Rusch VW, Rosenzweig KE: Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol; 2009 Jun;4(6):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.
  • INTRODUCTION: Multimodality therapy including extrapleural pneumonectomy (EPP), chemotherapy, and radiotherapy (RT) is often recommended for fit patients with early stage malignant pleural mesothelioma.
  • We studied patterns of local and nodal recurrence in patients treated at our institution with EPP and RT, and whether advanced treatment planning techniques, such as intensity modulated radiotherapy (IMRT), could have been of potential benefit.
  • METHODS: From 1993 to 2008, 86 patients with malignant pleural mesothelioma underwent EPP followed by hemithoracic RT (median dose: 54 Gy).
  • [MeSH-major] Mesothelioma / radiotherapy. Mesothelioma / surgery. Neoplasm Recurrence, Local / pathology. Photons. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / surgery. Pneumonectomy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404212.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Neragi-Miandoab S, Richards WG, Sugarbaker DJ: Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg; 2008 Aug;6(4):293-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
  • AIM: The survival of patients with malignant pleural mesothelioma (MPM) who do not seek treatment ranges from 4 to 12 months.
  • To date, the optimal procedure for resection of malignant pleural mesothelioma is controversial, extrapleural pneumonectomy has been most consistently associated with long-term survival and has provided the most radical cytoreduction; but, unfortunately, not all patients qualify for this invasive surgical approach.
  • Diagnosis was made by pleural biopsy via needle, open, or VATS biopsy.
  • CONCLUSION: Our results show that pleurectomy can be performed as a means of palliation for advanced-stage disease with a low mortality rate and may, in fact, improve survival in patients with epithelial subtype as compared with historical controls in the literature with no surgical intervention.
  • [MeSH-major] Cause of Death. Mesothelioma / mortality. Mesothelioma / surgery. Pleural Neoplasms / mortality. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Palliative Care / methods. Pleura / surgery. Postoperative Complications / mortality. Retrospective Studies. Risk Assessment. Survival Analysis. Thoracic Surgery, Video-Assisted / methods. Thoracic Surgery, Video-Assisted / mortality. Thoracotomy / methods. Thoracotomy / mortality. Time Factors. United States

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18585112.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Murdzhev K, Uchikov A, Iankulov A, Paskalev G: [Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma]. Khirurgiia (Sofiia); 2007;(4):23-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].
  • INTRODUCTION: Mesothelioma is characterized by aggressive follow-up, difficult diagnosis and treatment fatal issue.
  • In one side the restricted possibility for operative treatment and the other side the resistance of tumors for chemotherapy are the mean reasons for bad results in patients with malignant pleural mesothelioma.
  • We have aim to make a retrospective study of patients with malignant pleural mesothelioma in 3-th and 4-th stage, undergoing operation in our clinic and see VATS effectiveness.
  • PATIENTS AND METHODS: In the clinic of thoracic surgery in University Hospital "St.George" - Plovdiv we made retrospective study in 21 patients undergoing operation in the occasion of advanced pleural mesothelioma.
  • Before operation in this patients in help of diagnosis, we have information by image examination (radiography, CT of thorax and if it necessary to mark pleural effusion - sonography of pleural cavity ) abdominal sonohography or CT of abdomen for exclusion of distant metastasis, fibrobronchoscopy (FBS) for confirmation or exclusion of endobronchial cancer and transthoracic aspiration biopsy (TTAB).
  • Death issue in early postoperative period we have in 1 patient with increased breath insufficiency despite evacuation of pleural effusion and unfolded lung.
  • DISCUSSION: Early diagnosis of malignant pleural mesothelioma is difficult, in some times impossible.
  • Surgical treatment is decisive for diagnosis and treatment of malignant pleural mesothelioma even in advanced cases and have evident positive effects.
  • 3. VATS surgery is modern method for diagnosis and treatment and if it necessary we can continue by conventional operation for definitive treatment of mesothelioma.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms. Thoracic Surgery, Video-Assisted / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443531.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


32. Maeda R, Isowa N, Onuma H, Miura H, Touge H, Kawasaki Y: Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process. Gen Thorac Cardiovasc Surg; 2009 May;57(5):264-8
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process.
  • Early-stage malignant pleural mesothelioma (MPM) is difficult for physicians to diagnose, and the disease is usually advanced at the time of diagnosis.
  • A computed tomography scan (CT) of the chest showed a small amount of left pleural effusion and slight left pleural thickening that remained unchanged for 1 year.
  • One month after his inflammatory response spontaneously decreased, follow-up CT of the chest showed reduction in the effusion volume but no change in the pleural thickening.
  • Positron emission tomography with (18)F-fluorodeoxyglucose (FDG) showed increased FDG uptake in the pleural thickening on the left side.
  • Because MPM could not be ruled out, video-assisted thoracoscopic surgery with pleural biopsy was performed for a definitive diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440826.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Porta C, Ardizzoni A, Gaudino G, Maio M, Mutti L, Pinto C, Porru S, Puntoni R, Tassi G, Tognon M: Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group. Med Lav; 2005 Jul-Aug;96(4):360-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.
  • Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years.
  • To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe).
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Polyomavirus Infections / therapy. Tumor Virus Infections / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457433.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Cytokines; 0 / Protease Inhibitors; 0 / Protein Kinase Inhibitors; 1332-21-4 / Asbestos
  •  go-up   go-down


34. Adusumilli PS, Stiles BM, Chan MK, Mullerad M, Eisenberg DP, Ben-Porat L, Huq R, Rusch VW, Fong Y: Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med; 2006 May;8(5):603-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer that is refractory to current treatment modalities.
  • Furthermore, NV1066 was able to reduce the tumor burden and prolong survival even when treatment was at an advanced stage of the disease.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Meso-10 (CVCL_H668) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Meso-9 (CVCL_H669) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 John Wiley & Sons, Ltd.
  • [Cites] J Gene Med. 2003 Aug;5(8):681-9 [12898637.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1261-5 [3861775.001]
  • [Cites] J Occup Med. 1983 May;25(5):409-25 [6854431.001]
  • [Cites] Surgery. 2003 Aug;134(2):357-64 [12947341.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1053-60 [3473246.001]
  • [Cites] J Infect Dis. 1988 Sep;158(3):602-14 [2842408.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):313-21 [2165104.001]
  • [Cites] Semin Surg Oncol. 1990;6(5):279-85 [2237087.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):1001-6 [1588364.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1209-15 [8040888.001]
  • [Cites] Ann Thorac Surg. 1995 Apr;59(4):835-44 [7695406.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):466-71 [9012475.001]
  • [Cites] Am J Epidemiol. 1997 Feb 1;145(3):211-8 [9012593.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Gene Ther. 1998 Feb;5(2):160-5 [9578834.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):367-72 [9821167.001]
  • [Cites] Chest Surg Clin N Am. 1999 May;9(2):327-38, x [10365266.001]
  • [Cites] J Virol. 1999 Aug;73(8):6319-26 [10400723.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1599-606 [10428205.001]
  • [Cites] FASEB J. 1999 Aug;13(11):1325-34 [10428757.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] Gene Ther. 2000 May;7(10):859-66 [10845724.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):166-74 [10868479.001]
  • [Cites] Mol Ther. 2000 Dec;2(6):588-95 [11124059.001]
  • [Cites] World J Surg. 2001 Feb;25(2):210-7 [11338024.001]
  • [Cites] FASEB J. 2001 May;15(7):1306-8 [11344122.001]
  • [Cites] Ann Surg. 2001 Jun;233(6):819-26 [11371740.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):999-1010 [11387063.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Mol Med. 2001 Aug;7(8):561-8 [11591892.001]
  • [Cites] Gene Ther. 2002 Jan;9(1):75-80 [11850725.001]
  • [Cites] Hum Gene Ther. 2002 Jul 1;13(10):1213-23 [12133274.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):337-42; discussion 342-3 [12192320.001]
  • [Cites] Surgery. 2002 Aug;132(2):353-9 [12219034.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):95-100 [12242723.001]
  • [Cites] Cancer Gene Ther. 2002 Nov;9(11):935-45 [12386832.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:217-25 [12401694.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):967-78 [12522436.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):167-74 [12610498.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2629-30 [12860935.001]
  • (PMID = 16475242.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075416; United States / NCI NIH HHS / CA / R01 CA080982; United States / NCI NIH HHS / CA / R01 CA 75416; United States / NCI NIH HHS / CA / R01 CA/DK 80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS7189; NLM/ PMC1804293
  •  go-up   go-down


35. Paik PK, Krug LM: Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol; 2010 Feb;5(2):275-9
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
  • Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer of the mesothelium with only a limited range of treatment options that are largely ineffective in improving survival.
  • The results of these efforts have led to a multicenter, randomized, placebo-controlled phase III study of the histone deacetylase inhibitor vorinostat in patients with advanced MPM, offering hope for a new and effective therapy in patients with this disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors / pharmacology. Histone Deacetylase Inhibitors / therapeutic use. Hydroxamic Acids / pharmacology. Hydroxamic Acids / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Feb 10;24(7):1302-8 [15592515.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8 [11713097.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2586-96 [12239173.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1813-25 [15014036.001]
  • [Cites] Prostate. 2004 May 1;59(2):177-89 [15042618.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6962-8 [15501975.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] Mech Dev. 1993 Jan;40(1-2):85-97 [8382938.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1781-90 [8183577.001]
  • [Cites] J Pathol. 1997 Jan;181(1):67-74 [9072005.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8 [9475525.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Chest Surg Clin N Am. 1999 May;9(2):327-38, x [10365266.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] APMIS. 2005 Apr;113(4):264-8 [15865607.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1117-36, vii [16325127.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13548-58 [16533812.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98 [17428177.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3605-10 [17510206.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):931-8 [18064385.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5777-84 [18089875.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Thorac Oncol. 2009 Jan;4(1):97-101 [19096314.001]
  • [Cites] J Thorac Oncol. 2009 Feb;4(2):149-60 [19179889.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Apr;18(4):501-8 [19335278.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2818-28 [19351772.001]
  • [Cites] Cancer Causes Control. 2009 Aug;20(6):935-44 [19294523.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1409-20 [19509247.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3007-13 [19364962.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Jpn J Cancer Res. 2001 Dec;92(12):1300-4 [11749695.001]
  • (PMID = 20035240.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Number-of-references] 47
  • [Other-IDs] NLM/ NIHMS589324; NLM/ PMC4052955
  •  go-up   go-down


36. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR: Malignant pleural mesothelioma: a comprehensive review. Cancer Control; 2006 Oct;13(4):255-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: a comprehensive review.
  • BACKGROUND: The incidence of malignant mesothelioma continues to increase, but the disease remains difficult to detect early and treat effectively.
  • METHODS: The authors review the pathogenesis, incidence, clinical presentation, diagnosis, pathology, and both standard and experimental treatments for mesothelioma.
  • In patients with advanced disease, several newer antitumor agents are already showing a capability of extending survival so it is not unreasonable to expect further progress in this area.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Humans. Incidence. Magnetic Resonance Imaging. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / therapy. Tomography, X-Ray Computed. United States / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075562.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


37. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med; 2009 Jul;15(4):366-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and pleural fluid biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Malignant mesothelioma is an asbestos-induced, aggressive tumour.
  • In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring.
  • With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field.
  • The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease.
  • The assay has a high level of specificity relative to benign lung and pleural conditions and is positive in 10-15% of other malignancies.
  • SUMMARY: To date, soluble mesothelin remains the best available biomarker for malignant mesothelioma.
  • However, a lack of sensitivity for early-stage disease and for all malignant mesothelioma histologies provides motivation for the search of novel malignant mesothelioma biomarkers with greater sensitivity, especially for very early disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis
  • [MeSH-minor] GPI-Linked Proteins. Humans. Membrane Glycoproteins / metabolism. Osteopontin / metabolism. Pleural Cavity / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417672.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  • [Number-of-references] 52
  •  go-up   go-down


38. Chamberlain MH, Fareed K, Nakas A, Martin-Ucar AE, Waller DA: Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2008 Jul;34(1):200-3
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma.
  • OBJECTIVES: In the preoperative workup for radical surgery for malignant pleural mesothelioma (MPM), mediastinal lymph node staging, diagnostic pleural biopsies and effusion control with talc pleurodesis are required.
  • Following conventional cervical videomediastinoscopy, a 5 mm thoracoscope was advanced into the relevant pleural cavity through the mediastinoscope via a mediastinal pleurotomy.
  • Pleural biopsies were taken followed by talc insufflation and cervical tube drainage.
  • In five patients (three right and two left), thoracoscopy was abandoned due to excessive mediastinal fat (1), thick pleura (2) and inability to enter the left hemithorax (2).
  • VACT is feasible in right-sided mesothelioma but has not yet been validated on the left.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Pleurodesis / methods. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Drainage / methods. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / therapy. Talc / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18450462.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


39. Flores RM: Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer; 2005 Jul;49 Suppl 1:S71-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
  • Approximately 25% of patients with malignant pleural mesothelioma (MPM) prove unresectable at surgery and the median survival of stage III MPM is <12 months even after complete resection by extrapleural pneumonectomy.
  • Improving chemotherapy for MPM led us to test induction chemotherapy followed by EPP and adjuvant RT for locally advanced MPM to assess feasibility.
  • This combined modality approach is feasible for locally advanced MPM, and initial analysis suggests improved resectability.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15950805.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • RESULTS: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


41. Pilling J, Dartnell JA, Lang-Lazdunski L: Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg; 2010 Jun;58(4):215-9
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
  • INTRODUCTION: The results of trimodality therapy for malignant pleural mesothelioma (MPM) are related to stage.
  • CONCLUSIONS: In one of the few studies of integrated PET-CT in MPM that has complete pathological correlation we have shown that PET-CT does not accurately identify advanced tumor stage (T4) or mediastinal nodal disease (N2).
  • [MeSH-major] Fluorodeoxyglucose F18. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514576.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 14807-96-6 / Talc
  •  go-up   go-down


42. Tabata C, Hirayama N, Tabata R, Yasumitsu A, Yamada S, Murakami A, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Terada T, Nakano T: A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma. Eur Respir J; 2010 Nov;36(5):1099-105
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour associated with asbestos exposure that has only a limited response to conventional therapy; therefore, diagnosing MPM early is very important.
  • The patients with advanced-stage MPM showed higher levels of Ang-1 than the early-stage MPM patients and the Kaplan-Meier method revealed a significant correlation between serum Ang-1 levels and survival.
  • [MeSH-major] Angiopoietin-1 / blood. Angiopoietin-1 / genetics. Neoplasms, Mesothelial / metabolism. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185425.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Biomarkers; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


43. Luckraz H, Rahman M, Patel N, Szafranek A, Gibbs AR, Butchart EG: Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg; 2010 Mar;37(3):552-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
  • BACKGROUND: Optimal management of diffuse malignant pleural mesothelioma (DMPM) remains unclear.
  • Patients who only had pleural biopsies were excluded (n=78).
  • Surgical options were extra-pleural pneumonectomy (EPP) for Butchart stage I disease in clinically fit patients (n=49) or pleurectomy/decortication in patients who were either not fit for EPP or had advanced disease (Butchart stage II and III) or both (n=90).
  • CONCLUSIONS: In this series, cytoreductive surgery combined with post-operative adjuvant therapy provided better survival despite either advanced disease or surgically less fit patients.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19717307.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Scagliotti GV, Selvaggi G: Emerging drugs for mesothelioma. Expert Opin Emerg Drugs; 2007 Mar;12(1):127-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for mesothelioma.
  • Malignant mesothelioma is an aggressive, but relatively rare, malignancy, affecting the pleura and peritoneum.
  • The prognosis for malignant pleural mesothelioma (MPM) is poor, with median survival in the range of 8-14 months, depending on stage and presentation of disease.
  • In advanced disease not amenable to any local approach, such as surgery, combination chemotherapy represents the current standard of care.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355218.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


45. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M: Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol; 2008 Feb;19(2):370-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
  • BACKGROUND: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156144.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


46. Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S: Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. Oncol Res; 2006;16(5):235-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
  • Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients is therefore estimated to occur from 2010 to 2040 in Japan.
  • The inactivation of the MYO18B gene plays an important role in several malignant diseases.
  • Furthermore, it also suppressed the production of bloody pleural effusion after orthotopic injection.
  • These findings suggest that the restored expression of MYO18B may be a useful therapeutic strategy for the treatment of locally advanced MPM in humans.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Lung Neoplasms / genetics. Mesothelioma / genetics. Myosins / genetics. Myosins / pharmacology. Pleural Effusion / genetics. Pleural Neoplasms / genetics. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / pharmacology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294804.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYO18B protein, human; 0 / Tumor Suppressor Proteins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


47. Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T: TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res; 2010 Oct;30(10):4309-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
  • BACKGROUND: Recently, pemetrexed (PEM), a new generation antifolate, has been used for the treatment of patients with advanced non-squamous cell carcinoma (SQ) of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036757.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 0 / RNA, Messenger; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; EC 2.1.1.45 / Thymidylate Synthase; EC 2.1.2.2 / Phosphoribosylglycinamide Formyltransferase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M: Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res; 2009 Jan 1;15(1):382-9
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
  • EXPERIMENTAL DESIGN: Patients with malignant pleural mesothelioma or non-small cell lung cancer received pemetrexed doses from 500 to 900 mg/m(2) + 75 mg/m(2) cisplatin once every 21 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Glutamates / administration & dosage. Glutamates / pharmacokinetics. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy


49. Yamaoka N, Kawasaki Y, Xu Y, Yamamoto H, Terada N, Okamura H, Kubo S: Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma. Int J Oncol; 2010 Aug;37(2):273-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.
  • Malignant mesothelioma is a highly aggressive tumor with poor prognosis, and new treatment paradigms are urgently needed.
  • We developed in vivo fluorescence imaging models for human malignant mesothelioma in mice using tumor cells engineered to express fluorescent proteins (EGFP, mRFP, mCherry, and mPlum) by lentiviral vectors.
  • In both, peritoneally disseminated and orthotopic pleural mesothelioma models, mCherry-positive tumors were sensitively detected and tumor growth was successfully monitored.
  • This represents the first study to achieve sensitive tumor detection and tracking of tumor growth and development in the malignant mesothelioma mouse models by non-invasive in vivo fluorescence imaging.
  • These imaging models can be versatile and powerful tools to explore new treatment paradigms for malignant mesothelioma.
  • [MeSH-major] Diagnostic Imaging / methods. Disease Models, Animal. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596654.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Fluorescent Dyes
  •  go-up   go-down


50. Pehlivan B, Topkan E, Onal C, Nursal GN, Yuksel O, Dolek Y, Yavuz MN, Yavuz AA: Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma. Radiat Oncol; 2009;4:35
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
  • BACKGROUND: When combined with adequate tumoricidal doses, accurate target volume delineation remains to be the one of the most important predictive factors for radiotherapy (RT) success in locally advanced or medically inoperable malignant pleural mesothelioma (MPM) patients.
  • [MeSH-major] Mesothelioma / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiotherapy Planning, Computer-Assisted / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):6-7; discussion 8-9 [19695433.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):444-5 [11273069.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):1-9 [11750145.001]
  • [Cites] Radiother Oncol. 2002 Jan;62(1):51-60 [11830312.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1200-9 [12902408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] Clin Lung Cancer. 2004 Mar;5(5):290-8 [15086967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78-86 [15093902.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Jul;96(1):171-7 [3386291.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1157-68 [2666592.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] Radiology. 1991 Mar;178(3):705-13 [1847239.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6 [8813257.001]
  • [Cites] Eur Respir J. 1996 Dec;9(12):2565-72 [8980970.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):567-73 [15559064.001]
  • [Cites] Clin Nucl Med. 2005 Jul;30(7):470-7 [15965321.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5063-8 [16707428.001]
  • [Cites] Cancer Treat Rev. 2006 Jun;32(4):245-60 [16563636.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] Lung Cancer. 2007 Aug;57(2):125-34 [17478008.001]
  • [Cites] Radiother Oncol. 2008 Feb;86(2):251-7 [18207597.001]
  • [Cites] Med Dosim. 2008 Autumn;33(3):215-21 [18674686.001]
  • [Cites] Invest Radiol. 2008 Oct;43(10):737-44 [18791416.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:41 [18808725.001]
  • [Cites] Radiat Med. 2008 Dec;26(10):622-6 [19132495.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1413-8 [19224855.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3007-13 [19364962.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17(4):377-83 [10773558.001]
  • (PMID = 19758456.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2754492
  •  go-up   go-down


51. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP, EORTC-NCIC: Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol; 2007 Dec 20;25(36):5770-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
  • PURPOSE: Malignant pleural mesothelioma (MPM) is a rare disease.
  • Unlike other advanced cancer types, little is known about patient-reported symptoms or health-related quality of life (HRQOL) and their possible prognostic value.
  • CONCLUSION: Results suggest that the PI, pain, and appetite loss may be independent prognostic factors in patients with advanced MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Quinazolines / therapeutic use. Thiophenes / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089874.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


52. Lucchi M, Chella A, Melfi F, Dini P, Tibaldi C, Fontanini G, Mussi A: Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol; 2007 Mar;2(3):237-42
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-modality therapy in malignant pleural mesothelioma: a phase II study.
  • BACKGROUND: Treatment approaches in malignant pleural mesothelioma (MPM) patients range from mere palliation to aggressive anticancer therapy, and there is currently no consensus on the optimal therapeutic strategy.
  • In 1999, we began a phase II study to investigate four-modality treatment of advanced stage MPM.
  • METHODS: From 1999 to 2004, 49 patients with International Mesothelioma Interest Group stage II-III MPM underwent four-modality treatment with intrapleural preoperative interleukin-2 (18 x 10(6) UI/day for 3 days), pleurectomy/decortication, intrapleural postoperative epidoxorubicin (25 mg/m2 for 3 days), interleukin-2 (18 x 10(6) UI/day for 3 days), adjuvant radiotherapy (30 Gy), systemic chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2 days 1 and 8 for up to six courses) and long-term subcutaneous interleukin-2 (3 x 10(6) UI/day on 3 days per week).
  • CONCLUSION: The four-modality treatment that we adopted for advanced-stage MPM was feasible, well tolerated by most of the patients, and produced a favorable median survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Epirubicin / administration & dosage. Epirubicin / analogs & derivatives. Feasibility Studies. Female. Humans. Interleukin-2 / administration & dosage. Male. Middle Aged. Pleura / surgery. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410047.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Parente B: Mesothelioma treatment. Rev Port Pneumol; 2008 Jul;14 Suppl 2:S35-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma treatment.
  • [Transliterated title] Terapêutica do mesotelioma.
  • Malignant mesothelioma (MM) is a locally aggressive advanced tumour, with bad prognosis and many times fatal, who have been growing in the last two decades with possibilities to be continue in all the world until 2020, showing use of pic asbestos to the years 1960/1970.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967566.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Malignant pleural mesothelioma / Mesotelioma pleural maligno / chemotherapy / pemetrexed / quimioterapia / tratamento / treatment
  •  go-up   go-down


54. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA: Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg; 2008 Oct;34(4):886-91
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
  • OBJECTIVE: To identify the optimal debulking procedure in patients with malignant pleural mesothelioma who are not suitable for extrapleural pneumonectomy (EPP).
  • METHODS: We reviewed 102 consecutive patients (93 male; 9 female, mean age 63 years) who were not suitable for EPP because of either advanced tumour stage or suboptimal fitness.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656373.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G: Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial. In Vivo; 2006 Nov-Dec;20(6A):715-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
  • Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months.
  • Although multimodality protocols that combine aggressive surgery and adjuvant chemotherapy or radiotherapy have shown improved survival in selected cases, the majority of patients with MPM are not suitable for radical surgery due to advanced stage and comorbid medical illness.
  • The aim of this phase I-II study was to evaluate the toxicity profile and efficacy of two different platinum-based combined regimens--cisplatin plus mitomycin-C (MMC) and cisplatin plus melphalan (L-PAM)--administered using TSP technique in patients with advanced or recurrent MPM who had refractory disease after systemic first line chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy


56. Rezaei Kalantari H: [Malignant peritoneal mesothelioma: a case report]. Rev Med Liege; 2010 Sep;65(9):490-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma: a case report].
  • [Transliterated title] Le cas clinique du mois. Mésothéliome péritonéal malin.
  • I report two cases of malignant peritoneal mesothelioma.
  • Mesothelioma is mostly a pleural disease whether visceral or parietal.
  • Infra-diaphragmatic Mesothelioma accounts for only 10-20% of all mesotheliomas.
  • Sadly the disease is often unveiled at an advanced stage requiring palliative chemotherapy usually with a platin derivative or in a small percentage of the cases with abdominal radiotherapy to alleviate pain.
  • Prognosis for patients with malignant peritoneal mesothelioma is very poor with a mean survival of 5,4 months versus 12.5 months for pleural mesothelioma.
  • Peritoneal mesothelioma, although rare, should be considered among the differential diagnosis of ascites differential diagnosis work up.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086578.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


57. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther; 2007 Jul;6(7):1962-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
  • Malignant pleural mesothelioma (MPM) is a deadly disease with few systemic treatment options.
  • However, expression of activated Src (p-Src Y419) on the tumor cell membrane was higher in patients with advanced-stage disease; the presence of metastasis correlated with higher membrane (P = 0.03) and cytoplasmic (P = 0.04) expression of p-Src Y419.
  • Lower levels of membrane expression of inactive c-Src (p-Src Y530) correlated with advanced N stage (P = 0.02).
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Movement / drug effects. Mesothelioma / pathology. Pleural Neoplasms / pathology. Proto-Oncogene Proteins pp60(c-src) / antagonists & inhibitors. Pyrimidines / pharmacology. Thiazoles / pharmacology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620427.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src); RBZ1571X5H / Dasatinib
  •  go-up   go-down


58. Ambrosini V, Rubello D, Nanni C, Farsad M, Castellucci P, Franchi R, Fabbri M, Rampin L, Crepaldi G, Al-Nahhas A, Fanti S: Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur; 2005;8(2):111-5
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
  • BACKGROUND: Despite being a relatively rare disease, the incidence of malignant pleural mesothelioma (MPM) is expected to increase over the next two decades due to the long time interval elapsing between exposure to causative factors, mainly asbestos, and disease onset.
  • In more advanced disease stages, a multimodality treatment, including various combinations of chemotherapy, external radiotherapy and surgery, may provide some favourable results though the prognosis remains poor.
  • [MeSH-major] Mesothelioma / radiography. Mesothelioma / radionuclide imaging. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437396.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


59. Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T: Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Health Technol Assess; 2007 Jan;11(1):1-90
PubMed Health. PubMed Health .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
  • OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of pemetrexed disodium in combination with cisplatin for the treatment of unresectable pleural mesothelioma in chemotherapy-naive patients.
  • These findings were better for some patient subgroups, e.g. especially for fully supplemented (FS) patients with good performance status (0/1) and advanced disease (AD).
  • Cost-effectiveness seems better for some patient subgroups, e.g. especially for patients with good performance status and with advanced diseases, where it is estimated the ICER per QALY would be pound36,700.
  • Given the relatively small number of patients with mesothelioma, albeit increasing, the overall budget impact of pemetrexed would be unlikely to be more than pound5 million per year at present costs.
  • Much more research is needed into the optimum chemotherapy for patients with mesothelioma and a clear definition of what constitutes best supportive care.
  • [MeSH-major] Antineoplastic Agents / economics. Antineoplastic Agents / therapeutic use. Glutamates / economics. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy


60. Cicenas S, Vencevicius V: [Malignant pleural diseases: diagnosis and treatment]. Medicina (Kaunas); 2008;44(12):929-35
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural diseases: diagnosis and treatment].
  • OBJECTIVE: To evaluate efficacy of diagnostic procedures, results of surgery, and complications in malignant pleural diseases.
  • Patients were divided into two groups: group I, patients with primary pleural malignant diseases (93 patients, 55.0%), and group II, secondary pleural tumors (76 patients, 45%).
  • Of the 76 patients, 40 patients (52.6%) were diagnosed with metastatic pleural tumors and 36 patients (47.4%) with tumors invading parietal pleura.
  • Noninvasive methods included chest x-ray, chest computed tomography, magnetic resonance imaging, chest ultrasound, positron emission tomography/computed tomography (performed in Germany), and invasive methods included puncture of pleural effusions, transthoracic pleural puncture, drainage, pleural biopsy and video-assisted thoracoscopic pleural biopsy, pleural resection, and ultrasound-guided needle biopsy of the pleura.
  • The following procedures were performed in group I: pleurectomy in 15 patients (16.1%), pleural pneumonectomy in 42 patients (45.2%), pleural decortication in 12 patients (12.9%), extended pleuropneumonectomy with diaphragm and pericardium resections and plastic surgery in 14 patients (15.0%), pleurectomy with costal resections in 10 patients (10.1%).
  • Procedures performed in group II included video-assisted thoracoscopic pleurectomy in 15 patients (19.7%), pleural biopsy in 10 patients (13.2%), pleurectomy in 15 patients (19.7%), pleural drainage and fenestration in 5 patients (6.5%), lung and pleura resection in 12 patients (15.8%), chest wall and pleura resection in 10 patients (13.2%), diaphragm and pleura resections in 9 patients (11.8%).
  • RESULTS: Early stage primary pleural tumors were found in 24 patients (25.8%).
  • Metastatic pleural disease was found in 32 patients with early primary tumors (80.0%).
  • In all 36 patients (100.0%) with chest wall tumors, disease of advanced stage was determined.
  • In invasive methods, accuracies of pleural biopsy, video-assisted thoracoscopic pleural biopsy, and pleurectomy were 100%, 90%, and 100%, respectively.
  • In case of primary pleural tumors, the main surgery was extended pleuropulmonectomy (45.2%) with or without mediastinal resection.
  • In case of metastatic pleural disease, the main surgery was video-assisted thoracoscopic pleurectomy (19.7%).
  • In cases of pleural invasion by other thoracic malignancies, the main surgeries were chest wall and pleural resection (13.2%) and lung and pleural resection (15.8%).
  • After 169 operations due to malignant pleural diseases, the rate of postoperative complications ranged from 1.3% to 7.8%.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Data Interpretation, Statistical. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Pleura / pathology. Pleura / surgery. Pneumonectomy. Postoperative Complications. ROC Curve. Radiography, Thoracic. Sensitivity and Specificity. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142050.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


61. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA: DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer; 2007 Nov;58(2):220-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
  • Patients with malignant mesothelioma (MM), an aggressive cancer associated with asbestos exposure, usually present clinically with advanced disease and this greatly reduces the likelihood of curative treatment.
  • To exclude candidate MM markers that might be positive in biopsies/pleural fluid due to contaminating surrounding non-tumor lung tissue/DNA, we also examined the methylation of these markers in lung samples (age- or environmentally induced hypermethylation is frequently observed in non-cancerous lung).

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3080-97 [12912960.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4128-33 [12821947.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):786-92 [14999791.001]
  • [Cites] Occup Environ Med. 2004 May;61(5):438-41 [15090665.001]
  • [Cites] Environ Health Perspect. 2004 May;112(6):731-9 [15121517.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):361-71 [15488759.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1087-92 [15492797.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1172-8 [8501504.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2570-6 [10375104.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):150-7 [10395284.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):600-4 [15472908.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):193-204 [15639718.001]
  • [Cites] Occup Environ Med. 2005 Feb;62(2):134 [15657198.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1302-8 [15592515.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65-76 [15809275.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:629-56 [15822191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1274-8 [15894685.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Respirology. 2005 Jun;10(3):266-83 [15955137.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] Mol Cancer. 2005;4:42 [16351731.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 21;342(4):1228-32 [16516163.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1300-16 [16329111.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):656-67 [16575877.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):723-34 [16795078.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):109-16 [16893590.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10621-9 [17079487.001]
  • [Cites] Dis Markers. 2007;23(1-2):5-30 [17325423.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Curr Opin Pulm Med. 2000 Mar;6(2):157-63 [10741777.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;249:101-18 [10802941.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4556-60 [11389090.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5727-30 [11479207.001]
  • [Cites] Methods. 2001 Dec;25(4):456-62 [11846615.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):131-6 [12399123.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:827-30 [12426140.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):127-30 [12601276.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):735-44 [12640681.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):849-59 [14871960.001]
  • (PMID = 17659810.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA014089-349012; United States / NCI NIH HHS / CA / P30 CA014089; United States / NCI NIH HHS / CA / P30 CA 14089; United States / NCI NIH HHS / CA / P30 CA014089-349012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS33001; NLM/ PMC2752414
  •  go-up   go-down


62. Vogelzang NJ, Porta C, Mutti L: New agents in the management of advanced mesothelioma. Semin Oncol; 2005 Jun;32(3):336-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New agents in the management of advanced mesothelioma.
  • Malignant pleural mesothelioma (MPM) is a seemingly uncommon tumor whose incidence has in fact increased steadily and progressively over the last 30 years.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988688.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Proteasome Inhibitors; 0 / Ubiquitin; 0 / Vascular Endothelial Growth Factor A; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 3.1.- / Ribonucleases; EC 3.1.- / ranpirnase
  • [Number-of-references] 158
  •  go-up   go-down


63. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B: Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch; 2006 Jul;449(1):31-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
  • The aim of the present study was to evaluate HLA-G expression in breast carcinoma and malignant mesothelioma (MM).
  • Malignant breast carcinoma effusions (46) and corresponding solid tumors (39) and 104 MM (26 effusions, 78 solid tumors) were analyzed using immunohistochemistry (IHC).
  • However, the up-regulated expression of HLA-G in MM effusions and its possible association with shorter disease-free survival in advanced stage of breast carcinoma suggest a possible role in immune response evasion in some tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Mesothelioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / immunology. Ascitic Fluid / pathology. Biopsy. Female. Gene Expression. HLA-G Antigens. Humans. Male. Middle Aged. Pleural Effusion, Malignant / immunology. Pleural Effusion, Malignant / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):914-20 [12131159.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Acta Cytol. 1994 Nov-Dec;38(6):945-52 [7992584.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):18-25 [11836665.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):119-28 [14997042.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1954-60 [10213506.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5922-8 [9637505.001]
  • [Cites] Respiration. 1998;65(2):108-13 [9580921.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):243-50 [14639610.001]
  • [Cites] Eur J Surg Oncol. 1994 Feb;20(1):33-6 [8131866.001]
  • [Cites] Hum Immunol. 2005 Feb;66(2):164-9 [15695002.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1081-92 [14602239.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):512-8 [10225437.001]
  • [Cites] J Immunol Methods. 2002 Jun 1;264(1-2):109-19 [12191515.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):246-54 [15452897.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):42-7 [15589578.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] Microbes Infect. 2002 Dec;4(15):1539-44 [12505526.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):904-10 [15069585.001]
  • [Cites] Lung Cancer. 2004 May;44(2):159-65 [15084380.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1):54-75 [2579439.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7335-46 [15534110.001]
  • [Cites] Placenta. 2000 Mar-Apr;21 Suppl A:S86-92 [10831130.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):43-9 [10431845.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7167-75 [14612510.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1177-95 [11137224.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4107-11 [12874014.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):469-76 [15672872.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23 ):5490-8 [8968106.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • [Cites] Hum Immunol. 2002 Nov;63(11):969-76 [12392849.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):317-23 [14708711.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1405-12 [11684957.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3771-8 [7706718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):85-92 [12109861.001]
  • (PMID = 16541284.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; 0 / RNA, Messenger
  •  go-up   go-down


64. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol; 2005 Oct 1;23(28):6881-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
  • PURPOSE: We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome compared with cisplatin alone in patients with malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Eligible patients with histologically proven advanced MPM, not pretreated with chemotherapy, WHO performance status (PS) 0 to 2, and adequate hematological, renal, and hepatic function were randomly assigned to receive cisplatin 80 mg/m2 IV on day 1, alone (arm A) or combined with raltitrexed 3 mg/m2 (arm B).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192580.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-34
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C: Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol; 2010 May 20;28(15):2604-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
  • Hypervascularity is a prominent and poor-prognosis feature of malignant pleural mesothelioma (MPM).
  • CONCLUSION: The tolerability and disease control of NGR-hTNF 0.8 microg/m(2) weekly warrant additional evaluation in patients with advanced MPM.
  • [MeSH-major] Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Recombinant Fusion Proteins / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / tumor necrosis factor-alpha, CNGRC fusion protein, human
  •  go-up   go-down


66. Einhorn L: Perspective on the development of new agents in thoracic cancers. Lung Cancer; 2005 Oct;50 Suppl 1:S27-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291431.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


67. Motta AB, Pinheiro G, Antonângelo L, Parra ER, Monteiro MM, Pereira JC, Takagaki T, Terra Filho M, Martins S, Capelozzi VL: Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases. J Bras Pneumol; 2006 Jul-Aug;32(4):322-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases.
  • OBJECTIVE: Various markers have shown promise as diagnostic markers and prognostic predictors in malignant mesothelioma (MM).
  • Through immunohistochemistry, we confirmed 40 cases of mesothelioma and 11 cases of adenocarcinoma, although we were unable to classify 7 of the 8 cases presenting atypical histologic patterns.
  • Cox multivariate analysis revealed that the risk factor for death was higher (476.2) among patients of advanced age, presenting the biphasic subtype and testing positive for components expressed at the nuclear level.
  • CONCLUSION: The most useful immunohistochemical markers were was calretinin (for mesothelioma) and CEA (for adenocarcinoma).
  • Immunohistochemical quantification of thrombomodulin facilitated the diagnosis of mesothelioma in patients testing positive for both calretinin and CEA.
  • Therefore, histopathological analysis offers a powerful weapon with great potential to inform decisions regarding the use of adjuvant chemotherapy after surgical excision of a mesothelioma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268732.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Leu-M1 antigen; 0 / S100 Calcium Binding Protein G; 0 / Thrombomodulin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


68. Spugnini EP, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J Exp Clin Cancer Res; 2008;27:6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
  • Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans.
  • After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg.
  • The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carboplatin / administration & dosage. Cat Diseases / drug therapy. Dog Diseases / drug therapy. Mesothelioma / veterinary. Piroxicam / administration & dosage. Pleural Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Intern Med. 1999 Nov-Dec;13(6):529-33 [10587251.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):443-9 [18365537.001]
  • [Cites] J Small Anim Pract. 2000 Aug;41(8):342-7 [11002935.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3533-44 [12177114.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):148-56 [12601280.001]
  • [Cites] Dtsch Tierarztl Wochenschr. 2003 Apr;110(4):177-8 [12756962.001]
  • [Cites] Vet Pathol. 1978 Nov;15(6):781-3 [751315.001]
  • [Cites] Nihon Juigaku Zasshi. 1982 Dec;44(6):975-9 [7182639.001]
  • [Cites] Nihon Juigaku Zasshi. 1985 Jun;47(3):511-6 [4032940.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):86-91 [3543239.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Am J Vet Res. 1990 Oct;51(10):1682-7 [2240791.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Vet Intern Med. 1991 Jul-Aug;5(4):227-31 [1658318.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Comp Pathol. 1994 Nov;111(4):453-8 [7884062.001]
  • [Cites] Nat Med. 1997 Aug;3(8):913-6 [9256285.001]
  • [Cites] J Am Vet Med Assoc. 1997 Sep 15;211(6):736-40 [9301745.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Feline Med Surg. 2005 Oct;7(5):313-6 [15914055.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10120-1 [16267039.001]
  • [Cites] J Comp Pathol. 2006 May;134(4):347-54 [16712862.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(12):2000-4 [16963313.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133-43 [17062690.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):201-6 [10761756.001]
  • (PMID = 18577247.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2438333
  •  go-up   go-down


69. Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL: A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol; 2010 Oct;5(10):1655-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
  • HYPOTHESIS: Malignant mesotheliomas (MMs) express vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and cKIT.
  • We evaluated the activity of sorafenib in patients with unresectable mesothelioma.
  • CONCLUSION: Sorafenib has limited activity in advanced MM patients, similar to that seen with other VEGFR tyrosine kinase inhibitors.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2304-11 [19502050.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2081-90 [19255316.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):94-7 [18486273.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1962-72 [17620427.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Cancer Lett. 2006 Aug 8;239(2):183-9 [16216411.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Lung Cancer. 2005 May;48(2):291-6 [15829331.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2221-30 [10327068.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):529-39 [9872600.001]
  • [Cites] Oncogene. 1991 Nov;6(11):2005-11 [1658707.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 20736856.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / R01 CA135257; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS229523; NLM/ PMC3823555
  •  go-up   go-down


70. Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM: Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res; 2010 May 15;16(10):2872-80
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC.
  • EXPERIMENTAL DESIGN: Patients with TSF (pleural effusions, ascites) and relapsed, stage III/IV NSCLC or malignant pleural/peritoneal mesothelioma were treated with pemetrexed (500 mg/m2) on day 1 of each 21-day cycle.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Ascites / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / pharmacokinetics. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Middle Aged. Neoplasm Staging. Pemetrexed. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Pleural Neoplasms / complications. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR.
  • (PMID = 20460481.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


71. Simon F, Johnen G, Krismann M, Müller KM: Chromosomal alterations in early stages of malignant mesotheliomas. Virchows Arch; 2005 Oct;447(4):762-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations in early stages of malignant mesotheliomas.
  • In a case of a 67-year-old man with two different early stages of a predominantly epithelioid mesothelioma ("mesothelioma in situ", "early-stage mesothelioma"), chromosomal imbalances were determined by comparative genomic hybridisation (CGH), a molecular cytogenetic technique to detect chromosomal gains and losses in tumour cells.
  • In the case of the mesothelioma in situ cells, nine different chromosomal alterations could be detected (losses on 3p, 5q, 6q, 8p, 9p, 15q, 22q, Y; gain on 7q), whereas the early-stage mesothelioma showed the same defects except for the gain on 7q.
  • The simultaneous losses of 6q, 9p and 22q, as well as other chromosomal regions, correlate well with the most common defects previously found in 90 cases of more-advanced-stage mesotheliomas using CGH.
  • The molecular cytogenetic findings support the histological diagnosis of a pleural mesothelioma.
  • The surprisingly high number and extent of genomic alterations found in the examined case probably reflects the genomic instability in the tumour cells and indicates a "genetic chaos" even in earlier stages of malignant mesotheliomas.
  • [MeSH-major] DNA, Neoplasm / genetics. Mesothelioma / genetics. Mesothelioma / pathology. Pleural Neoplasms / genetics. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Chromosome Aberrations. Humans. Immunohistochemistry. Lasers. Male. Microdissection. Nucleic Acid Hybridization. Pleural Effusion / pathology. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1992 Jul;13(3):718-25 [1639399.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Hum Pathol. 1996 Apr;27(4):342-9 [8617476.001]
  • [Cites] Int J Oncol. 2003 May;22(5):1009-17 [12684666.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):248-55 [11037344.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Feb;18(2):94-101 [9115969.001]
  • [Cites] Br J Cancer. 1998;77(2):260-9 [9460997.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1159-61 [15475955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4494-9 [10200290.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Chest. 1996 Jan;109(1):109-14 [8549169.001]
  • [Cites] J Pathol. 2002 Jul;197(3):363-71 [12115883.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):209-16 [11232111.001]
  • [Cites] J Pathol. 1999 Oct;189(2):150-4 [10547567.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Semin Diagn Pathol. 1992 May;9(2):151-61 [1609157.001]
  • (PMID = 16012846.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


72. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer; 2009 Nov;66(2):141-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in the treatment of advanced non-squamous lung cancer.
  • Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma.
  • The next step was to test pemetrexed plus cisplatin versus gemcitabine plus cisplatin, as first-line therapy in advanced NSCLC patients, in a phase III, non-inferiority, randomized trial.
  • The role of pemetrexed as maintenance therapy after first-line therapy for advanced NSCLC is currently being evaluated into a phase III trial.
  • To date, pemetrexed is registered, at the dose of 500 mg/m(2) on day 1 of a 3-week schedule, in combination with cisplatin, for first-line therapy and, as single-agent, for second-line treatment of patients with non-squamous NSCLC.This review shows the latest and indicates the future developments of pemetrexed in the treatment of advanced NSCLC patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577816.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biological Products; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 59
  •  go-up   go-down


73. Okishiro N, Tanimukai H, Tsuneto S, Ito N: Can "steroid switching" improve steroid-induced psychosis in a patient with advanced cancer? J Palliat Med; 2009 May;12(5):487-90
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can "steroid switching" improve steroid-induced psychosis in a patient with advanced cancer?
  • We experienced the case of 67-year-old man with malignant pleural mesothelioma and pulmonary emphysema who developed psychiatric symptoms after switching from oral prednisolone 10 mg/day to intravenous betamethasone 2 mg/day.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BETAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416050.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9842X06Q6M / Betamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


74. Bellmunt J, Delgado FM, George C: Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol; 2008 Jun;35(3 Suppl 3):S34-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors.
  • Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma.
  • Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Clinical Trials as Topic. Humans. Mesothelioma / drug therapy. Mice. Pleural Neoplasms / drug therapy. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538178.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tubulin Modulators; 5BF646324K / vinflunine; 5V9KLZ54CY / Vinblastine
  • [Number-of-references] 52
  •  go-up   go-down


75. Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther; 2005 Sep;27(9):1343-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The US Food and Drug Administration approved pemetrexed in February 2004 for the treatment of malignant pleural mesothelioma (MPM) in combination with cisplatin in patients with unresectable disease or for whom curative surgery is not an option.
  • In August 2004, pemetrexed was approved as a second-line, single-agent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
  • Search terms included pemetrexed, Alimta, MTA, multitargeted antifolate, LY231514, mesothelioma, MPM, non-small cell lung cancer, NSCLC, breast cancer, and pancreatic cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Folic Acid Antagonists / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291410.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 162
  •  go-up   go-down


76. Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC: Pemetrexed-induced pneumonitis: a case report. Clin Lung Cancer; 2009 Sep;10(5):364-6
Hazardous Substances Data Bank. CIPROFLOXACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology.
  • Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19808196.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5E8K9I0O4U / Ciprofloxacin; 5Z93L87A1R / Guanine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Davidson B: Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog; 2007 Dec;13(3):189-227
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of cancer cells in effusions within the serosal (peritoneal, pleural, and pericardial) cavities is a clinical manifestation of advanced-stage cancer and is associated with poor survival.
  • Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site.
  • In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298385.001).
  • [ISSN] 0893-9675
  • [Journal-full-title] Critical reviews in oncogenesis
  • [ISO-abbreviation] Crit Rev Oncog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / EFN-4 protein, C elegans; 0 / Ephrins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, Growth Factor
  • [Number-of-references] 167
  •  go-up   go-down


78. Meriggi F, Di Biasi B, Caliolo C, Zaniboni A: The potential role of pemetrexed in gastrointestinal cancer. Chemotherapy; 2008;54(1):1-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2004, the new-generation multitargeted antifolate pemetrexed was approved by the US Food and Drug Administration for the treatment of malignant pleural mesothelioma and as second-line monochemotherapy for advanced non-small cell lung cancer.
  • In phase II studies exploring this multitargeted antifolate in advanced gastrointestinal tumors, pemetrexed showed an interesting degree of clinical activity, encouraging further trials evaluating the synergism with other drugs such as oxaliplatin, irinotecan and gemcitabine.

  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18063861.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 59
  •  go-up   go-down


79. Scagliotti GV: Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer. Lung Cancer; 2005 Oct;50 Suppl 1:S18-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small-cell lung cancer (NSCLC) and treatment of malignant pleural mesothelioma.
  • In untreated advanced NSCLC, single-agent activity has been demonstrated in phase II trials.
  • With its innovative mode of action, proven efficacy, favorable toxicity profile and convenient administration, pemetrexed represents a new therapeutic option for the treatment of advanced NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291426.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


80. Sudoh J, Gemma A: [Pemetrexed]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1033-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed (ALIMTA, LY231514) is a novel, multi targeted antifolate chemotherapy agent that is active in various tumors including mesothelioma, NSCLC, breast, colon and bladder carcinoma.
  • Pemetrexed is approved in the United States and a number of European Union countries for use in the treatment of mesothelioma, and the second-line treatment of advanced NSCLC.
  • However, in Japan, pemetrexed was approved for use only in combination with cisplatin in the treatment of mesothelioma in January 2007.
  • This approval was granted on the basis of a phase III trial of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633241.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


81. Martin M: Clinical experience with pemetrexed in breast cancer. Semin Oncol; 2006 Feb;33(1 Suppl 2):S15-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed possesses antitumor activity in several solid tumors, including non-small cell lung cancer, malignant pleural mesothelioma, pancreas, colorectal, gastric, bladder, breast, and head and neck cancers.
  • Pemetrexed has been tested in five phase II trials in locally advanced or metastatic breast cancer.
  • The drug has shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472713.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  • [Number-of-references] 24
  •  go-up   go-down


82. Zhang Y, Trissel LA: Physical instability of frozen pemetrexed solutions in PVC bags. Ann Pharmacother; 2006 Jul-Aug;40(7-8):1289-92
Hazardous Substances Data Bank. POLYVINYL CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pemetrexed is a multitargeted antifolate antineoplastic agent indicated for single-agent use in advanced or metastatic non-small-cell lung cancer and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery.

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822897.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 451W47IQ8X / Sodium Chloride; 5Z93L87A1R / Guanine; 9002-86-2 / Polyvinyl Chloride; IY9XDZ35W2 / Glucose
  •  go-up   go-down


83. Manegold C, Schmid-Bindert G, Pilz LR: Pemetrexed for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther; 2009 Sep;9(9):1195-209
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is a novel multi-targeted antifolate that is used in the treatment of both malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC).
  • This refers to the greater efficacy of pemetrexed in patients with advanced NSCLC other than of predominantly squamous-cell histology.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761423.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 129
  •  go-up   go-down


84. Zhang Y, Trissel LA: Physical and chemical stability of pemetrexed in infusion solutions. Ann Pharmacother; 2006 Jun;40(6):1082-5
Hazardous Substances Data Bank. POLYVINYL CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pemetrexed is a multitargeted, antifolate, antineoplastic agent that is indicated for single-agent use in locally advanced or metastatic non-small-cell lung cancer after prior chemotherapy and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery.

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720706.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Pharmaceutical Solutions; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 9002-86-2 / Polyvinyl Chloride
  •  go-up   go-down


85. Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E: Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol; 2007 Aug;14(4):154-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article, we discuss the biologic and clinical rationales that have recently led the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group to initiate four phase ii trials testing this agent in the following four different tumour types: relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1994 Feb;21(1):54-62 [8310310.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):792-5 [8622025.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):500-2 [9155539.001]
  • [Cites] Br J Cancer. 1997;76(9):1221-7 [9365173.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):8-12 [10431840.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):777-82 [10717248.001]
  • [Cites] Blood. 2000 Jul 1;96(1):282-7 [10891463.001]
  • [Cites] Exp Hematol. 2000 Sep;28(9):993-1000 [11008011.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):167-72 [11191056.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):213-5 [11354055.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3658-61 [11369666.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4341-4 [11389057.001]
  • [Cites] Med Oncol. 2001;18(4):269-75 [11918453.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22 [12040530.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):469-75 [12051876.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93 [12359857.001]
  • [Cites] Mol Pathol. 2002 Dec;55(6):348-59 [12456770.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):377-82 [12538491.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Adv Exp Med Biol. 2003;522:83-97 [12674213.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):673-9 [13130314.001]
  • [Cites] Blood. 1992 Oct 15;80(8):2142-8 [1356515.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):107-18 [15168728.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2893-902 [15238424.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):489-501 [15516973.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):101-11 [15652753.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):902-5 [15721449.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4626-33 [15911865.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Dec;315(3):971-9 [16002463.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1345-51 [16109613.001]
  • [Cites] Curr Opin Oncol. 2005 Nov;17(6):611-6 [16224242.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii13-viii19 [16239232.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):389-93 [1999708.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1079-85 [3894589.001]
  • [Cites] Radiother Oncol. 1995 May;35(2):107-17 [7569018.001]
  • [Cites] Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805-7 [8456884.001]
  • (PMID = 17710208.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1948864
  •  go-up   go-down


86. Esteban E, Casillas M, Cassinello A: Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev; 2009 Jun;35(4):364-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is an antitumor agent traditionally used as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) as well as in combination with cisplatin for the treatment of chemonaïve patients with unresectable malignant pleural mesothelioma.
  • Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269106.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 76
  •  go-up   go-down


87. Belvedere O, Grossi F: Lung Cancer Highlights from ASCO 2005. Oncologist; 2006 Jan;11(1):39-50
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Eastern Cooperative Oncology Group 4599 phase III trial showed superior survival in patients with advanced nonsquamous NSCLC when the angiogenesis inhibitor bevacizumab was added to standard first-line chemotherapy with carboplatin and paclitaxel, compared with the same chemotherapy alone.
  • Unfortunately, no striking results have been reported for small cell lung cancer and pleural malignant mesothelioma.

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401712.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


88. Zhang Y, Trissel LA: Physical and chemical stability of pemetrexed solutions in plastic syringes. Ann Pharmacother; 2005 Dec;39(12):2026-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pemetrexed is a multitargeted antifolate antineoplastic agent that is indicated for single-agent use in advanced or metastatic non-small-cell lung cancer and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery.

  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227449.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Excipients; 0 / Glutamates; 0 / Pharmaceutical Solutions; 0 / Plastics; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


89. Lopes G, Vincek V, Raez LE: Pemetrexed-associated urticarial vasculitis. Lung Cancer; 2006 Feb;51(2):247-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer.

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Hives.
  • MedlinePlus Health Information. consumer health - Rashes.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360237.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


90. Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK: Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis. Crit Rev Oncol Hematol; 2008 Jul;67(1):64-70
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 28% had non-small cell lung cancer, 41% pancreatic cancer, and 31% had malignant pleural mesothelioma that was either locally advanced or metastatic.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Rev Oncol Hematol. 2008 Jul;67(1):62-3 [18359243.001]
  • (PMID = 18358737.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down






Advertisement